Oleksandr Abaturov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Oleksandr Abaturov has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
A.P. Volosovets
Bogomolets National Medical University, Kyiv, Ukraine
41 shared publications- A. O. Nikulina
Dnipro State Medical University, Dnipro, Ukraine
33 shared publications - V. L. Babуch
Dnipro State Medical University, Dnipro, Ukraine
33 shared publications Т.а. Kryuchko
Ukrainian Medical Stomatological Academy, Poltava, Ukraine
18 shared publicationsYe.I. Yulish
17 shared publicationsT.P. Borysova
State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine
14 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 31 (3) , 124-131
Genotypic and demographic factors of the therapy effectiveness in different phenotypic trajectories of atopic dermatitis in children
Genetic predisposition, sex, and age at disease onset play an important role in the pathogenesis of atopic dermatitis (AD) and the effectiveness of its treatment in children. To date, insufficient data are available regarding the influence of these factors on changes in clinical symptoms’ dynamics (CSD) of AD during standard therapy (ST). The aim of this study was to determine the role of different genotypes of the single nucleotide variant (SNV) rs7927894 of the filaggrin (FLG) gene, sex, and age in the effectiveness of standard therapy, as assessed by changes in CSD across different phenotypic trajectories (PhT) of atopic dermatitis in children. The study group comprised 29 children divided into three subgroups: 9 children with a mono-organ PhT (MOPhT) of AD, 10 children with a poly-organ PhT (POPhT) of AD + allergic rhinitis/rhinoconjunctivitis (AR/ARC), and 10 children with a poly-organ POPhT representing a completed atopic march (AD + AR/ARC + bronchial asthma (BA)). All children in the three subgroups underwent genotyping of buccal swab samples using real-time polymerase chain reaction (qPCR) to determine the C/T, C/C, and T/T genotypes of the SNV rs7927894 of the FLG gene. The Scoring Atopic Dermatitis (SCORAD) index was used to assess clinical symptoms dynamics at the beginning and at the end of follow-up (FU), with values presented as medians and interquartile ranges – Me [LQ-HQ]. The mean FU duration was 1.5 [1.1; 2.0] years (range, 1-2.4 years). Improvement (a decrease in the SCORAD index) during ST for AD was observed significantly more frequently in children aged 7-11 years (86%, p=0.008) and in carriers of the heterozygous C/T genotype of the SNV rs7927894 FLG (75%, p=0.005). In patients with AD MOPhT, whose baseline SCORAD values did not differ significantly (32.2 [14.2; 45.8] and 32.5 [31.4; 43.3], p=0.796), worsening of CSD was observed as an increase of 8.0 points (p=0.108), whereas improvement was detected by a significant decrease in the index of 8.5 points (p=0.043). The final significant difference between worsening and improvement in CSD, as assessed by SCORAD, was 16.8 points (p=0.020).In patients with POPhT of AD + AR/ARC, whose baseline SCORAD values did not differ significantly (29.9 [23.2; 34.8] and 37.2 [27.1; 39.4], p=0.336), worsening of CSD was detected as an increase of 3.4 points (p=0.144), while improvement was detected by a significant decrease in the index of 14.7 points (p=0.028). Following ST, the difference between worsening and improvement in CSD for this PhT of AD was 10.8 points (p=0.055). In patients with POPhT of AD + AR/ARC + BA, whose baseline SCORAD values did not differ significantly (22.8 [14.2; 29.7] and 26.6 [18.5; 51.2], p=0.569), worsening of CSD was detected as an increase in the index of 6.3 points (p=0.109), whereas improvement was demonstrated by a significant decrease of 12.3 points (p=0.028). Following ST, the difference between worsening and improvement in CSD for this PhT of AD was statistically significant at 14.8 points (p=0.038). Standard therapy for AD is most frequently effective in improving the clinical symptoms dynamics among patients aged 7-11 years. The heterozygous C/T genotype of the SNV rs7927894 FLG is most frequently associated with the effectiveness of standard therapy in improving the clinical symptoms dynamics of AD, in 75% of patients. A more precise assessment of the effectiveness of standard therapy on the clinical symptoms dynamics in children with mono-organ and poly-organ phenotypic trajectories of AD requires investigation of the maximal spectrum of genotypic and demographic factors in larger patient cohorts, at the background of using the combinations of follow-up assessment tools.
- 30 September 2026
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 31 (3) , 124-131
Open AccessGenotypic and demographic factors of the therapy effectiveness in different phenotypic trajectories of atopic dermatitis in children
Genetic predisposition, sex, and age at disease onset play an important role in the pathogenesis of atopic dermatitis (AD) and the effectiveness of its treatment in children. To date, insufficient data are available regarding the influence of these factors on changes in clinical symptoms’ dynamics (CSD) of AD during standard therapy (ST). The aim of this study was to determine the role of different genotypes of the single nucleotide variant (SNV) rs7927894 of the filaggrin (FLG) gene, sex, and age in the effectiveness of standard therapy, as assessed by changes in CSD across different phenotypic trajectories (PhT) of atopic dermatitis in children. The study group comprised 29 children divided into three subgroups: 9 children with a mono-organ PhT (MOPhT) of AD, 10 children with a poly-organ PhT (POPhT) of AD + allergic rhinitis/rhinoconjunctivitis (AR/ARC), and 10 children with a poly-organ POPhT representing a completed atopic march (AD + AR/ARC + bronchial asthma (BA)). All children in the three subgroups underwent genotyping of buccal swab samples using real-time polymerase chain reaction (qPCR) to determine the C/T, C/C, and T/T genotypes of the SNV rs7927894 of the FLG gene. The Scoring Atopic Dermatitis (SCORAD) index was used to assess clinical symptoms dynamics at the beginning and at the end of follow-up (FU), with values presented as medians and interquartile ranges – Me [LQ-HQ]. The mean FU duration was 1.5 [1.1; 2.0] years (range, 1-2.4 years). Improvement (a decrease in the SCORAD index) during ST for AD was observed significantly more frequently in children aged 7-11 years (86%, p=0.008) and in carriers of the heterozygous C/T genotype of the SNV rs7927894 FLG (75%, p=0.005). In patients with AD MOPhT, whose baseline SCORAD values did not differ significantly (32.2 [14.2; 45.8] and 32.5 [31.4; 43.3], p=0.796), worsening of CSD was observed as an increase of 8.0 points (p=0.108), whereas improvement was detected by a significant decrease in the index of 8.5 points (p=0.043). The final significant difference between worsening and improvement in CSD, as assessed by SCORAD, was 16.8 points (p=0.020).In patients with POPhT of AD + AR/ARC, whose baseline SCORAD values did not differ significantly (29.9 [23.2; 34.8] and 37.2 [27.1; 39.4], p=0.336), worsening of CSD was detected as an increase of 3.4 points (p=0.144), while improvement was detected by a significant decrease in the index of 14.7 points (p=0.028). Following ST, the difference between worsening and improvement in CSD for this PhT of AD was 10.8 points (p=0.055). In patients with POPhT of AD + AR/ARC + BA, whose baseline SCORAD values did not differ significantly (22.8 [14.2; 29.7] and 26.6 [18.5; 51.2], p=0.569), worsening of CSD was detected as an increase in the index of 6.3 points (p=0.109), whereas improvement was demonstrated by a significant decrease of 12.3 points (p=0.028). Following ST, the difference between worsening and improvement in CSD for this PhT of AD was statistically significant at 14.8 points (p=0.038). Standard therapy for AD is most frequently effective in improving the clinical symptoms dynamics among patients aged 7-11 years. The heterozygous C/T genotype of the SNV rs7927894 FLG is most frequently associated with the effectiveness of standard therapy in improving the clinical symptoms dynamics of AD, in 75% of patients. A more precise assessment of the effectiveness of standard therapy on the clinical symptoms dynamics in children with mono-organ and poly-organ phenotypic trajectories of AD requires investigation of the maximal spectrum of genotypic and demographic factors in larger patient cohorts, at the background of using the combinations of follow-up assessment tools.
- Open Access
- 29 September 2026
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 60 (3) , 234-243
Epigenetic antifibrotic effect of expression of long non-coding RNAs GAS5, MEG8, FLRL2 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease: systematic review
Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) — and its progressive inflammatory stage, metabolic dysfunction-associated steatohepatitis (MASH) — has emerged as one of the most frequent causes of liver fibrosis. In the context of MASLD, fibrogenesis is governed by a highly complex interplay of intracellular signaling pathways that are epigenetically modulated by long non-coding RNAs (lncRNAs). The purpose was to systematically evaluate the epigenetic impact of reduced expression of antifibrotic lncRNAs (GAS5, MEG8, FLRL2) on the development and progression of liver fibrosis in MASLD/MASH, with emphasis on key profibrotic signalling pathways ((PI3K/Akt, Wnt/β-catenin, Notch, Arntl/Sirt1) and therapeutic perspectives. Materials and methods. This systematic review was conducted and reported in accordance with the PRISMA 2020 statement (PROSPERO registration CRD420250652980). A comprehensive search of PubMed, Cochrane Library, Scopus, Embase, and Web of Science (2010–2026) was performed using predefined Boolean strings. Original clinical, animal, and in vitro studies that demonstrated reduced expression of the target antifibrotic lncRNAs and their association with increased fibrosis or hepatic stellate cell activation in established MASLD/MASH models or human cohorts were included. Two independent reviewers performed study selection, data extraction, and risk-of-bias assessment (SYRCLE for animal studies, ROBINS-I for observational clinical studies, modified OHAT for in vitro studies). Results. Of 106 identified reports, 42 addressed lncRNAs (GAS5, MEG8, FLRL2) expression as potential biomarkers; ultimately, 8 studies met strict inclusion criteria. Reduced expression of GAS5, MEG8, FLRL2 was consistently associated with hepatic stellate cell activation, epithelial-mesenchymal transition, and activation of the main profibrotic pathways, leading to increased α-SMA and COL1A1 expression. Conclusions. GAS5, MEG8, FLRL2 play a significant epigenetic role in the development of advanced liver fibrosis in MASLD/MASH. A decrease in their expression leads to derepression of profibrotic signaling in key profibrotic signaling pathways (PI3K/Akt, Wnt/β-catenin, Notch, Arntl/Sirt1).
- 29 September 2026
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 60 (3) , 234-243
Open AccessEpigenetic antifibrotic effect of expression of long non-coding RNAs GAS5, MEG8, FLRL2 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease: systematic review
Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) — and its progressive inflammatory stage, metabolic dysfunction-associated steatohepatitis (MASH) — has emerged as one of the most frequent causes of liver fibrosis. In the context of MASLD, fibrogenesis is governed by a highly complex interplay of intracellular signaling pathways that are epigenetically modulated by long non-coding RNAs (lncRNAs). The purpose was to systematically evaluate the epigenetic impact of reduced expression of antifibrotic lncRNAs (GAS5, MEG8, FLRL2) on the development and progression of liver fibrosis in MASLD/MASH, with emphasis on key profibrotic signalling pathways ((PI3K/Akt, Wnt/β-catenin, Notch, Arntl/Sirt1) and therapeutic perspectives. Materials and methods. This systematic review was conducted and reported in accordance with the PRISMA 2020 statement (PROSPERO registration CRD420250652980). A comprehensive search of PubMed, Cochrane Library, Scopus, Embase, and Web of Science (2010–2026) was performed using predefined Boolean strings. Original clinical, animal, and in vitro studies that demonstrated reduced expression of the target antifibrotic lncRNAs and their association with increased fibrosis or hepatic stellate cell activation in established MASLD/MASH models or human cohorts were included. Two independent reviewers performed study selection, data extraction, and risk-of-bias assessment (SYRCLE for animal studies, ROBINS-I for observational clinical studies, modified OHAT for in vitro studies). Results. Of 106 identified reports, 42 addressed lncRNAs (GAS5, MEG8, FLRL2) expression as potential biomarkers; ultimately, 8 studies met strict inclusion criteria. Reduced expression of GAS5, MEG8, FLRL2 was consistently associated with hepatic stellate cell activation, epithelial-mesenchymal transition, and activation of the main profibrotic pathways, leading to increased α-SMA and COL1A1 expression. Conclusions. GAS5, MEG8, FLRL2 play a significant epigenetic role in the development of advanced liver fibrosis in MASLD/MASH. A decrease in their expression leads to derepression of profibrotic signaling in key profibrotic signaling pathways (PI3K/Akt, Wnt/β-catenin, Notch, Arntl/Sirt1).
- Open Access
- 17 September 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 3,p. 5-14
Applying the principles of 5P medicine to the prevention and treatment of childhood obesity: from genetic prediction to precision therapy (review)
The spread of obesity among children and adolescents has reached pandemic proportions and leads to the development of severe cardiometabolic disorders, which significantly reduces the duration and quality of life. Since standard clinical recommendations demonstrate insufficient long-term effectiveness, there is an urgent need to change the paradigm and implement a proactive health care model based on the concept of 5P-medicine. Objective — to substantiate and propose for implementation in pediatric practice a holistic methodological model of obesity management in children and adolescents, built on the five principles of 5P-medicine (predictability, prevention, personalization, participation and precision) to increase the effectiveness of treatment, improve compliance and reduce the risk of complications. Materials and methods. The work was performed in the format of a narrative literature review with elements of a systematic search according to the PRISMA 2020 methodology in the international databases PubMed/MEDLINE, Scopus, Web of Science and Google Scholar for the period from January 1, 2015 to June 30, 2026. Of more than 680 identified sources, after deduplication and screening, 21 publications were included in the final analysis. Methodological quality was assessed using validated tools AMSTAR-2, Cochrane RoB 2, NOS, SANRA and JBI.Results and discussion. The evidence base of the review was formed based on the analysis of 21 key studies of high (Level A, 8 works) and moderate (Level B, 13 works) levels of evidence with a wide geography and sample power. Data synthesis demonstrated the following patterns across the 5P domains: Predictive: focuses on polygenic risk scores, targeted sequencing to detect monogenic forms, and epigenetic markers. Preventive: focuses on modifying risk factors in the «first 1000 days of life» (nutrition, microbiome formation). Precision/Personalized: reflects phenotype-oriented therapy, the use of artificial intelligence, and targeted pharmacotherapy. Participatory/Digital: demonstrates the high effectiveness of family involvement through digital family platforms and cognitive behavioral therapy. Conclusions. The management of childhood obesity is finally transforming from template approaches to personalized precision medicine that takes into account the genetic profile, microbiome state, and patient phenotype.
- 17 September 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 3,p. 5-14
Open AccessApplying the principles of 5P medicine to the prevention and treatment of childhood obesity: from genetic prediction to precision therapy (review)
The spread of obesity among children and adolescents has reached pandemic proportions and leads to the development of severe cardiometabolic disorders, which significantly reduces the duration and quality of life. Since standard clinical recommendations demonstrate insufficient long-term effectiveness, there is an urgent need to change the paradigm and implement a proactive health care model based on the concept of 5P-medicine. Objective — to substantiate and propose for implementation in pediatric practice a holistic methodological model of obesity management in children and adolescents, built on the five principles of 5P-medicine (predictability, prevention, personalization, participation and precision) to increase the effectiveness of treatment, improve compliance and reduce the risk of complications. Materials and methods. The work was performed in the format of a narrative literature review with elements of a systematic search according to the PRISMA 2020 methodology in the international databases PubMed/MEDLINE, Scopus, Web of Science and Google Scholar for the period from January 1, 2015 to June 30, 2026. Of more than 680 identified sources, after deduplication and screening, 21 publications were included in the final analysis. Methodological quality was assessed using validated tools AMSTAR-2, Cochrane RoB 2, NOS, SANRA and JBI.Results and discussion. The evidence base of the review was formed based on the analysis of 21 key studies of high (Level A, 8 works) and moderate (Level B, 13 works) levels of evidence with a wide geography and sample power. Data synthesis demonstrated the following patterns across the 5P domains: Predictive: focuses on polygenic risk scores, targeted sequencing to detect monogenic forms, and epigenetic markers. Preventive: focuses on modifying risk factors in the «first 1000 days of life» (nutrition, microbiome formation). Precision/Personalized: reflects phenotype-oriented therapy, the use of artificial intelligence, and targeted pharmacotherapy. Participatory/Digital: demonstrates the high effectiveness of family involvement through digital family platforms and cognitive behavioral therapy. Conclusions. The management of childhood obesity is finally transforming from template approaches to personalized precision medicine that takes into account the genetic profile, microbiome state, and patient phenotype.
- Open Access
- 28 May 2026
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 4(156),p. 105-118
Pathogenetic role of cellular senessence in juvenile idiopathic arthritis and systemic lupus erythematosus: a narrative literature review
According to epidemiological studies, the prevalence of systemic autoimmune diseases (SADs) is increasing annually, and the leading positions in the pediatric nosological structure are consistently occupied by juvenile idiopathic arthritis, systemic lupus erythematosus, and juvenile dermatomyositis. Despite the introduction of biological and targeted disease-modifying therapies, chronic inflammation and the risk of infectious complications remain a pressing problem, which necessitates the search for new pathogenetically based approaches, in particular those related to the mechanisms of immunosenescence. Aim - to assess the impact of cellular senescence on the development of juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE), to determine its clinical significance in terms of the activity of the pathological process, resistance to therapy, and prognosis of the disease course. Narrative literature review with elements of systematic search according to PRISMA 2020 recommendations. Proinflammatory cytokines (IL-1β, IL-6, TNF-α) are the main triggers of senescence of immunocytes and tissue cells. In JIA, the process is predominantly local in nature (synovia). Senescent fibroblasts and T-cells produce TNF-α, IL-6, matrix metalloproteinases, which leads to joint damage. In SLE, senescence is systemic. Premature aging is observed in immunocytes, including B cells, podocytes, endothelium, and microglia, which is analyzed in the development of lupus nephritis and CNS damage. Senescence markers (p16INK4a, p21CIP1, SA-β-gal, telomere shortening) are promising biomarkers of activity and prognosis of autoimmune diseases. Conclusions. Cellular senescence is an important factor accompanying the adverse course of JIA and SLE. A promising direction for maintaining remission may be the use of senolytics and senomodifiers. Further pediatric studies are needed to validate biomarkers and therapeutic targets. The authors declare no conflict of interest.
- 28 May 2026
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 4(156),p. 105-118
Open AccessPathogenetic role of cellular senessence in juvenile idiopathic arthritis and systemic lupus erythematosus: a narrative literature review
According to epidemiological studies, the prevalence of systemic autoimmune diseases (SADs) is increasing annually, and the leading positions in the pediatric nosological structure are consistently occupied by juvenile idiopathic arthritis, systemic lupus erythematosus, and juvenile dermatomyositis. Despite the introduction of biological and targeted disease-modifying therapies, chronic inflammation and the risk of infectious complications remain a pressing problem, which necessitates the search for new pathogenetically based approaches, in particular those related to the mechanisms of immunosenescence. Aim - to assess the impact of cellular senescence on the development of juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE), to determine its clinical significance in terms of the activity of the pathological process, resistance to therapy, and prognosis of the disease course. Narrative literature review with elements of systematic search according to PRISMA 2020 recommendations. Proinflammatory cytokines (IL-1β, IL-6, TNF-α) are the main triggers of senescence of immunocytes and tissue cells. In JIA, the process is predominantly local in nature (synovia). Senescent fibroblasts and T-cells produce TNF-α, IL-6, matrix metalloproteinases, which leads to joint damage. In SLE, senescence is systemic. Premature aging is observed in immunocytes, including B cells, podocytes, endothelium, and microglia, which is analyzed in the development of lupus nephritis and CNS damage. Senescence markers (p16INK4a, p21CIP1, SA-β-gal, telomere shortening) are promising biomarkers of activity and prognosis of autoimmune diseases. Conclusions. Cellular senescence is an important factor accompanying the adverse course of JIA and SLE. A promising direction for maintaining remission may be the use of senolytics and senomodifiers. Further pediatric studies are needed to validate biomarkers and therapeutic targets. The authors declare no conflict of interest.
- Open Access
- 27 May 2026
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 60 (2) , 133-143
Epigenetic antifibrotic effect of expression of long noncoding RNAs lncR-p21, MEG3, H19 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease (systematic review and meta-analysis)
Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common chronic liver disorders in children and adults worldwide. Liver fibrosis is the key prognostic factor determining disease progression to cirrhosis and hepatocellular carcinoma. Long non-coding RNAs (lncRNAs) have emerged as critical epigenetic regulators of hepatic stellate cell (HSC) activation and fibrogenesis. The purpose was to systematically evaluate the epigenetic impact of reduced expression of anti-fibrotic long non-coding RNAs (lncR-p21, MEG3, and H19) on the development and progression of liver fibrosis in MASLD/MASH, with emphasis on key profibrotic signaling pathways (TGF-β/SMAD, Hedgehog) and therapeutic perspectives. Materials and methods. This systematic review and meta-analysis was conducted and reported in accordance with the PRISMA 2020 statement (PROSPERO registration CRD420250652980). A comprehensive search of PubMed, Cochrane Library, Scopus, Embase, and Web of Science (2010–2026) was performed using predefined Boolean strings. Original clinical, animal, and in vitro studies that demonstrated reduced expression of the target anti-fibrotic lncRNAs and their association with increased fibrosis or HSC activation in established MASLD/MASH models or human cohorts were included. Two independent reviewers performed study selection, data extraction, and risk-of-bias assessment (SYRCLE for animal studies, ROBINS-I for observational clinical studies, modified OHAT for in vitro studies). Quantitative meta-analysis is planned when at least three comparable studies per lncRNAs are available. Results. Of 106 identified reports, 53 addressed lncRNAs (lncR-p21, MEG3, H19) expression as potential biomarkers; ultimately, 7 studies met strict inclusion criteria. Reduced expression of lncR-p21, MEG3, and H19 was consistently associated with HSC activation, epithelial-mesenchymal transition, and activation of the main profibrotic pathways, leading to increased α-SMA and COL1A1 expression. Conclusions. LncR-p21, MEG3, H19 play a significant epigenetic role in the development of advanced liver fibrosis in MASLD/MASH. A decrease in their expression leads to derepression of profibrotic signaling in key profibrotic signaling pathways (TGF-β/SMAD, Hedgehog).
- 27 May 2026
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 60 (2) , 133-143
Open AccessEpigenetic antifibrotic effect of expression of long noncoding RNAs lncR-p21, MEG3, H19 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease (systematic review and meta-analysis)
Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common chronic liver disorders in children and adults worldwide. Liver fibrosis is the key prognostic factor determining disease progression to cirrhosis and hepatocellular carcinoma. Long non-coding RNAs (lncRNAs) have emerged as critical epigenetic regulators of hepatic stellate cell (HSC) activation and fibrogenesis. The purpose was to systematically evaluate the epigenetic impact of reduced expression of anti-fibrotic long non-coding RNAs (lncR-p21, MEG3, and H19) on the development and progression of liver fibrosis in MASLD/MASH, with emphasis on key profibrotic signaling pathways (TGF-β/SMAD, Hedgehog) and therapeutic perspectives. Materials and methods. This systematic review and meta-analysis was conducted and reported in accordance with the PRISMA 2020 statement (PROSPERO registration CRD420250652980). A comprehensive search of PubMed, Cochrane Library, Scopus, Embase, and Web of Science (2010–2026) was performed using predefined Boolean strings. Original clinical, animal, and in vitro studies that demonstrated reduced expression of the target anti-fibrotic lncRNAs and their association with increased fibrosis or HSC activation in established MASLD/MASH models or human cohorts were included. Two independent reviewers performed study selection, data extraction, and risk-of-bias assessment (SYRCLE for animal studies, ROBINS-I for observational clinical studies, modified OHAT for in vitro studies). Quantitative meta-analysis is planned when at least three comparable studies per lncRNAs are available. Results. Of 106 identified reports, 53 addressed lncRNAs (lncR-p21, MEG3, H19) expression as potential biomarkers; ultimately, 7 studies met strict inclusion criteria. Reduced expression of lncR-p21, MEG3, and H19 was consistently associated with HSC activation, epithelial-mesenchymal transition, and activation of the main profibrotic pathways, leading to increased α-SMA and COL1A1 expression. Conclusions. LncR-p21, MEG3, H19 play a significant epigenetic role in the development of advanced liver fibrosis in MASLD/MASH. A decrease in their expression leads to derepression of profibrotic signaling in key profibrotic signaling pathways (TGF-β/SMAD, Hedgehog).
- Open Access
- 13 May 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (3) , 347-358
Epigenetic influence of long non-coding RNAs on the development of metabolic-associated steatohepatitis
Background. Long non-coding RNAs (lncR) are characterized by a high degree of tissue-specific gene expression, allowing certain combinations to be considered as diagnostic markers of metabolic-associated steatohepatitis (MASH). The purpose of this literature review is to present current data on the role of long non-coding RNAs in the epigenetic influence on the development of metabolic-associated steatohepatitis, based on analysis of contemporary scientific literature. Materials and methods. An analysis of 76 literature sources from the past five years was conducted using the databases MEDLINE, Embase, PreMedline In-Process & Other Non-Indexed Citations, The Cochrane Systematic Reviews Database, DARE, NHS EED and HTA databases, Web of Knowledge Science Citation Index, Web of Knowledge ISI Proceedings, CRD databases, and BIOSIS. Sources were selected using the keywords: long non-coding steatogenic RNAs, epigenetic regulation, metabolically associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, obesity. PROSPERO registration: CRD420250652980. Literature analysis. Temporal analysis showed that periodic fluctuations in the expression of most lncR lead to both inflammation development and production of pro-inflammatory cytokines. Inhibition of the transcription factor NF-κB suppresses the expression activity of most pro-inflammatory lncR. Long non-coding RNAs participate in the development of MASH primarily by activating pro-inflammatory signaling pathways, transcription factors (NF-κB, AP-1), and inflammasomes. By regulating the expression levels of cytokines (IL-1β, IL-6, TNF) and chemokines (CCL2, CXCL1, CXCL5), lncR determine the recruitment of pro-inflammatory immune cells, local vascular response, and, consequently, the degree of inflammatory reaction in liver tissue in metabolic dysfunction-associated steatotic liver disease. Conclusions. Pro-inflammatory and anti-inflammatory lncR are epigenetic regulators of liver inflammation that determine the development of MASH and may be considered potential targets for anti-inflammatory pharmacotherapy in patients with MASH.
- 13 May 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (3) , 347-358
Open AccessEpigenetic influence of long non-coding RNAs on the development of metabolic-associated steatohepatitis
Background. Long non-coding RNAs (lncR) are characterized by a high degree of tissue-specific gene expression, allowing certain combinations to be considered as diagnostic markers of metabolic-associated steatohepatitis (MASH). The purpose of this literature review is to present current data on the role of long non-coding RNAs in the epigenetic influence on the development of metabolic-associated steatohepatitis, based on analysis of contemporary scientific literature. Materials and methods. An analysis of 76 literature sources from the past five years was conducted using the databases MEDLINE, Embase, PreMedline In-Process & Other Non-Indexed Citations, The Cochrane Systematic Reviews Database, DARE, NHS EED and HTA databases, Web of Knowledge Science Citation Index, Web of Knowledge ISI Proceedings, CRD databases, and BIOSIS. Sources were selected using the keywords: long non-coding steatogenic RNAs, epigenetic regulation, metabolically associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, obesity. PROSPERO registration: CRD420250652980. Literature analysis. Temporal analysis showed that periodic fluctuations in the expression of most lncR lead to both inflammation development and production of pro-inflammatory cytokines. Inhibition of the transcription factor NF-κB suppresses the expression activity of most pro-inflammatory lncR. Long non-coding RNAs participate in the development of MASH primarily by activating pro-inflammatory signaling pathways, transcription factors (NF-κB, AP-1), and inflammasomes. By regulating the expression levels of cytokines (IL-1β, IL-6, TNF) and chemokines (CCL2, CXCL1, CXCL5), lncR determine the recruitment of pro-inflammatory immune cells, local vascular response, and, consequently, the degree of inflammatory reaction in liver tissue in metabolic dysfunction-associated steatotic liver disease. Conclusions. Pro-inflammatory and anti-inflammatory lncR are epigenetic regulators of liver inflammation that determine the development of MASH and may be considered potential targets for anti-inflammatory pharmacotherapy in patients with MASH.
- Open Access
- 31 March 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 1,p. 23-30
Kallmann syndrome type 2 associated with a rare missense mutation in the FGFR1 gene: a clinical case report
Kallmann syndrome (KS) is a rare congenital form of isolated hypogonadotropic hypogonadism (IHH) associated with anosmia or hyposmia due to impaired migration of GnRH and olfactory neurons during embryogenesis. Objective — to describe the diagnostic work-up and clinical course of a rare case of KS type 2 associated with a mutation in the FGFR1 gene and to substantiate the initial hormone replacement therapy strategy to optimize early detection and management algorithms in pediatric endocrinology practice. Materials and methods. A systematic analysis of 23 contemporary peer-reviewed sources (PubMed/MEDLINE, Scopus, Web of Science) was performed with emphasis on clinical manifestations, genotype—phenotype correlations and differential diagnosis. The clinical case of a 17-year-old Ukrainian boy was reported in accordance with CARE guidelines and with informed parental consent. Comprehensive evaluation included medical history, physical examination, hormonal profiling, bone-age radiography, brain MRI with contrast, olfactometry, scrotal ultrasound, karyotyping and targeted next-generation sequencing (targeted next-generation sequencing (tNGS) panel for hypogonadotropic hypogonadism/Disorders of Sex Development) of 93 genes performed in a certified laboratory (Labcorp/Invitae, USA). Results and discussion. Molecular genetic analysis identified a rare heterozygous missense variant rs1064793123 in the FGFR1 gene (c.1019C>T). This study presents the first comprehensive clinical characterization of this variant with new phenotypic manifestations, additional evidence of pathogenicity, and practical algorithms for pediatric endocrinology in Ukraine. Conclusions. The case emphasizes the need for mandatory assessment of olfactory function in all adolescents with delayed puberty and early initiation of replacement therapy to prevent psychosocial and somatic complications.
- 31 March 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Journal of Pediatric Endocrinology
- No. 1,p. 23-30
Open AccessKallmann syndrome type 2 associated with a rare missense mutation in the FGFR1 gene: a clinical case report
Kallmann syndrome (KS) is a rare congenital form of isolated hypogonadotropic hypogonadism (IHH) associated with anosmia or hyposmia due to impaired migration of GnRH and olfactory neurons during embryogenesis. Objective — to describe the diagnostic work-up and clinical course of a rare case of KS type 2 associated with a mutation in the FGFR1 gene and to substantiate the initial hormone replacement therapy strategy to optimize early detection and management algorithms in pediatric endocrinology practice. Materials and methods. A systematic analysis of 23 contemporary peer-reviewed sources (PubMed/MEDLINE, Scopus, Web of Science) was performed with emphasis on clinical manifestations, genotype—phenotype correlations and differential diagnosis. The clinical case of a 17-year-old Ukrainian boy was reported in accordance with CARE guidelines and with informed parental consent. Comprehensive evaluation included medical history, physical examination, hormonal profiling, bone-age radiography, brain MRI with contrast, olfactometry, scrotal ultrasound, karyotyping and targeted next-generation sequencing (targeted next-generation sequencing (tNGS) panel for hypogonadotropic hypogonadism/Disorders of Sex Development) of 93 genes performed in a certified laboratory (Labcorp/Invitae, USA). Results and discussion. Molecular genetic analysis identified a rare heterozygous missense variant rs1064793123 in the FGFR1 gene (c.1019C>T). This study presents the first comprehensive clinical characterization of this variant with new phenotypic manifestations, additional evidence of pathogenicity, and practical algorithms for pediatric endocrinology in Ukraine. Conclusions. The case emphasizes the need for mandatory assessment of olfactory function in all adolescents with delayed puberty and early initiation of replacement therapy to prevent psychosocial and somatic complications.
- Open Access
- 28 March 2026
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 2(154),p. 7-19
Efficacy of probiotic bacteria Bacillus clausii in the treatment of acute gastroenteritis in children
Aim - to systematically review contemporary evidence on the efficacy of Bacillus clausii strains in the treatment of acute gastroenteritis (AGE) in children, assess the degree of inconsistency in the evidence base, and propose practical recommendations for pediatric clinical practice. Narrative literature review with systematic search in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar (2000-2026). PRISMA 2020 guidelines were followed. Fifty-four full-text articles (original studies, systematic reviews, and meta-analyses) containing data on Bacillus clausii use in children with acute gastroenteritis were included. No meta-analysis was performed due to data heterogeneity; qualitative synthesis was applied. The mixture of Bacillus clausii strains (O/C, N/R, SIN, T) reduces the duration of diarrhea by an average of 9-14 hours, with a moderate standardized effect size, decreases stool frequency, and promotes faster clinical recovery in children with AGE, including rotavirus etiology. The effect is most pronounced during the first 3-5 days of treatment and in young children. Results of individual randomized trials are heterogeneous, ranging from statistically significant reduction of diarrhea duration by 12-34 hours to no significant difference compared to placebo. The preparation demonstrates a high safety profile and good tolerability without serious adverse events. Conclusions. Bacillus clausii-based preparations may be recommended as adjunctive therapy in children with AGE, particularly within the first 24-48 hours of diarrhea onset, to shorten clinical manifestations and prevent severe dehydration. Further high-quality randomized trials are required to clarify strain-specific effects and definitively establish the role of Bacillus clausii in treatment algorithms. The authors declare no conflict of interest.
- 28 March 2026
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 2(154),p. 7-19
Open AccessEfficacy of probiotic bacteria Bacillus clausii in the treatment of acute gastroenteritis in children
Aim - to systematically review contemporary evidence on the efficacy of Bacillus clausii strains in the treatment of acute gastroenteritis (AGE) in children, assess the degree of inconsistency in the evidence base, and propose practical recommendations for pediatric clinical practice. Narrative literature review with systematic search in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar (2000-2026). PRISMA 2020 guidelines were followed. Fifty-four full-text articles (original studies, systematic reviews, and meta-analyses) containing data on Bacillus clausii use in children with acute gastroenteritis were included. No meta-analysis was performed due to data heterogeneity; qualitative synthesis was applied. The mixture of Bacillus clausii strains (O/C, N/R, SIN, T) reduces the duration of diarrhea by an average of 9-14 hours, with a moderate standardized effect size, decreases stool frequency, and promotes faster clinical recovery in children with AGE, including rotavirus etiology. The effect is most pronounced during the first 3-5 days of treatment and in young children. Results of individual randomized trials are heterogeneous, ranging from statistically significant reduction of diarrhea duration by 12-34 hours to no significant difference compared to placebo. The preparation demonstrates a high safety profile and good tolerability without serious adverse events. Conclusions. Bacillus clausii-based preparations may be recommended as adjunctive therapy in children with AGE, particularly within the first 24-48 hours of diarrhea onset, to shorten clinical manifestations and prevent severe dehydration. Further high-quality randomized trials are required to clarify strain-specific effects and definitively establish the role of Bacillus clausii in treatment algorithms. The authors declare no conflict of interest.
- Open Access
- 27 March 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 222-230
Epigenetic influence of long non-coding steatogenic RNAs on the development of metabolic dysfunction-associated steatotic liver disease
Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in humans, which is caused by changes in the expression level of long non-coding RNAs (lncRs). The aim of this literature review is to present a brief description of the role of steatogenic lncRs in the epigenetic influence on the development of MASLD, analyzing the data of modern scientific literature. Materials and methods. An analysis of 60 literature sources over the past five years was conducted from the databases MEDLINE; Embase; PreMedline In-Process & Other Non-Indexed Citations; The Cochrane Systematic Reviews Database, DARE, NHS EED and HTA databases; Web of Knowledge Science Citation Index; Web of Knowledge ISI Proceedings; CRD databases; BIOSIS, which were selected using the following keywords: long non-coding RNAs, epigenetic regulation, metabolically associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease obesity. PROSPERO CRD420250652980. Results. Increased expression of steatogenic lncRs, such as CCAT1, Gm10804, Gm15622, H19, HOTAIR, lncARSR, NEAT1, PVT1, SRA, Uc.372, is a characteristic feature of the development and progression of hepatic steatosis in MASLD. The development of hepatic steatosis in MASLD is supported by a decrease in the expression level of anti-steatotic lncRs, including AC012668, FLRL2, Gm16551, lncHR1, B4GALT1-AS1/lncSHGL, MEG3, lncR MRAK052686. Conclusions. Long noncoding RNAs have an unconditional pathogenetic influence on the main mechanisms of the development of hepatic steatosis in MASLD, promoting lipid uptake in hepatocytes, enhancing de novo lipogenesis, inhibiting β-oxidation of fatty acids and lipid export from hepatocytes.
- 27 March 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (2) , 222-230
Open AccessEpigenetic influence of long non-coding steatogenic RNAs on the development of metabolic dysfunction-associated steatotic liver disease
Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in humans, which is caused by changes in the expression level of long non-coding RNAs (lncRs). The aim of this literature review is to present a brief description of the role of steatogenic lncRs in the epigenetic influence on the development of MASLD, analyzing the data of modern scientific literature. Materials and methods. An analysis of 60 literature sources over the past five years was conducted from the databases MEDLINE; Embase; PreMedline In-Process & Other Non-Indexed Citations; The Cochrane Systematic Reviews Database, DARE, NHS EED and HTA databases; Web of Knowledge Science Citation Index; Web of Knowledge ISI Proceedings; CRD databases; BIOSIS, which were selected using the following keywords: long non-coding RNAs, epigenetic regulation, metabolically associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease obesity. PROSPERO CRD420250652980. Results. Increased expression of steatogenic lncRs, such as CCAT1, Gm10804, Gm15622, H19, HOTAIR, lncARSR, NEAT1, PVT1, SRA, Uc.372, is a characteristic feature of the development and progression of hepatic steatosis in MASLD. The development of hepatic steatosis in MASLD is supported by a decrease in the expression level of anti-steatotic lncRs, including AC012668, FLRL2, Gm16551, lncHR1, B4GALT1-AS1/lncSHGL, MEG3, lncR MRAK052686. Conclusions. Long noncoding RNAs have an unconditional pathogenetic influence on the main mechanisms of the development of hepatic steatosis in MASLD, promoting lipid uptake in hepatocytes, enhancing de novo lipogenesis, inhibiting β-oxidation of fatty acids and lipid export from hepatocytes.
- Open Access
- 1 January 2026
- Published by Publishing House Helvetica (Publications)
- No. 2 (199),p. 49-55
ROLE OF THE SINGLE-NUCLEOTIDE VARIANT RS17492553 OF THE UMAMI RECEPTOR GENE TAS1R1 IN THE DEVELOPMENT OF METABOLICALLY UNHEALTHY OBESITY IN CHILDREN
Background. Altered umami taste perception associated with the single nucleotide variant (SNV) in the taste 1 receptor member 1 (TAS1R1) gene may contribute to excess fat accumulation and predict the obesity phenotype. Objective: To determine the risk of developing metabolically unhealthy obesity in children with SNV rs17492553 TAS1R1. Methods. 350 children with obesity aged 6–18 years were examined. Among obese children, two observation subgroups with metabolically unhealthy obesity (MUO, n = 204) and metabolically healthy obesity (MHO, n = 146), were separated. The level of basal glycemia, insulinemia was studied by immunochemical method with electrochemiluminescent detection, high-density lipoproteins and triglycerides – by enzymatic-colorimetric method in the Synevo (Ukraine). SNVs of the TAS1R1 gene were identified by whole-genome next- generation sequencing in 52 children at the CeGaT laboratory (Germany). Results. Of the six identified SNVs (rs10864628, rs17492553, rs34160967, rs35118458, rs35375392, rs41278020) of TAS1R1, only SNV rs17492553 was associated with the development of MUO, determining an increase in gonadotropins and a decrease in 25-hydroxycalciferol in serum. Conclusions. Carriers of the CT genotype of SNV rs17492553 TAS1R1 are 2.73 times more likely to develop metabolically unhealthy obesity than CC homozygotes. Актуальність. SNV rs17492553 гена TAS1R1 впливає на сприйняття смаку умамі, що може сприяти розвитку ожиріння. Мета: оцінити ризик метаболічно нездорового ожиріння (metabolically unhealthy obesity – MUO) у дітей із варіантом гена TAS1R1. Методи. Обстежено 350 дітей (6–18 років) з ожирінням: 204 з MUO та 146 з метаболічно здоровим типом (metabolically healthy obesity – MHO). Показники глікемії, інсуліну та ліпідного профілю визначали методами Synevo. Секвенування генома 52 дітей про- ведено в лабораторії CeGaT (Німеччина). Результати. Серед шести виявлених SNV лише rs17492553 корелював із MUO. Він асоціювався з підвищенням рівнів гонадотро- пінів та зниженням вітаміну D (25-гідроксикальциферолу) в сироватці. Висновки. Носії CT-генотипу rs17492553 мають ризик розвитку MUO у 2,73 раза вищий, ніж СС-гомозиготи.
- 1 January 2026
- Published by Publishing House Helvetica (Publications)
- No. 2 (199),p. 49-55
Open AccessROLE OF THE SINGLE-NUCLEOTIDE VARIANT RS17492553 OF THE UMAMI RECEPTOR GENE TAS1R1 IN THE DEVELOPMENT OF METABOLICALLY UNHEALTHY OBESITY IN CHILDREN
Background. Altered umami taste perception associated with the single nucleotide variant (SNV) in the taste 1 receptor member 1 (TAS1R1) gene may contribute to excess fat accumulation and predict the obesity phenotype. Objective: To determine the risk of developing metabolically unhealthy obesity in children with SNV rs17492553 TAS1R1. Methods. 350 children with obesity aged 6–18 years were examined. Among obese children, two observation subgroups with metabolically unhealthy obesity (MUO, n = 204) and metabolically healthy obesity (MHO, n = 146), were separated. The level of basal glycemia, insulinemia was studied by immunochemical method with electrochemiluminescent detection, high-density lipoproteins and triglycerides – by enzymatic-colorimetric method in the Synevo (Ukraine). SNVs of the TAS1R1 gene were identified by whole-genome next- generation sequencing in 52 children at the CeGaT laboratory (Germany). Results. Of the six identified SNVs (rs10864628, rs17492553, rs34160967, rs35118458, rs35375392, rs41278020) of TAS1R1, only SNV rs17492553 was associated with the development of MUO, determining an increase in gonadotropins and a decrease in 25-hydroxycalciferol in serum. Conclusions. Carriers of the CT genotype of SNV rs17492553 TAS1R1 are 2.73 times more likely to develop metabolically unhealthy obesity than CC homozygotes. Актуальність. SNV rs17492553 гена TAS1R1 впливає на сприйняття смаку умамі, що може сприяти розвитку ожиріння. Мета: оцінити ризик метаболічно нездорового ожиріння (metabolically unhealthy obesity – MUO) у дітей із варіантом гена TAS1R1. Методи. Обстежено 350 дітей (6–18 років) з ожирінням: 204 з MUO та 146 з метаболічно здоровим типом (metabolically healthy obesity – MHO). Показники глікемії, інсуліну та ліпідного профілю визначали методами Synevo. Секвенування генома 52 дітей про- ведено в лабораторії CeGaT (Німеччина). Результати. Серед шести виявлених SNV лише rs17492553 корелював із MUO. Він асоціювався з підвищенням рівнів гонадотро- пінів та зниженням вітаміну D (25-гідроксикальциферолу) в сироватці. Висновки. Носії CT-генотипу rs17492553 мають ризик розвитку MUO у 2,73 раза вищий, ніж СС-гомозиготи.